As advances in interventional psychiatry continue to reshape depression treatment, clinicians are increasingly exploring how brain stimulation interacts with existing medication regimens. A recent analysis of clinical data examining TMS with antipsychotic augmentation provides new insight into whether these medications alter the effectiveness of transcranial magnetic stimulation.
The study, published in the Journal of Psychopharmacology and available through research on the future of interventional psychiatry, analyzed real-world treatment outcomes from two independent TMS clinics in Germany. Investigators evaluated whether patients taking antipsychotic medications alongside antidepressants responded differently to repetitive transcranial magnetic stimulation (rTMS) or intermittent theta burst stimulation (iTBS).
The findings contribute to a practical question many clinicians face when managing complex depressive disorders that require multiple treatment strategies.
The Role Of TMS In Modern Depression Treatment
Transcranial magnetic stimulation has become an established noninvasive neuromodulation therapy for major depressive disorder. By delivering magnetic pulses to targeted brain regions, particularly the dorsolateral prefrontal cortex, TMS can modulate neural circuits involved in mood regulation.
Both standard rTMS and the newer iTBS protocol have demonstrated efficacy for treatment resistant depression in controlled clinical trials. Because many patients receiving TMS have complex treatment histories, it is common for stimulation therapy to be delivered alongside ongoing pharmacological treatment.
Antipsychotic medications are frequently prescribed as augmentation strategies when antidepressants alone fail to produce sufficient improvement. However, clinicians have long questioned whether these medications might influence the neurophysiological effects of brain stimulation.
Some researchers have speculated that antipsychotic medications could dampen cortical excitability, potentially interfering with stimulation-based therapies. Evidence on this interaction has remained limited.
Investigating TMS With Antipsychotic Augmentation Across Two Clinical Sites
To explore this question, researchers conducted a naturalistic analysis using clinical records from two specialized TMS outpatient departments located in Augsburg and Regensburg.
The Augsburg cohort included 53 patients, while the Regensburg dataset included 120 patients receiving TMS treatment for depressive symptoms. Depression severity was measured using established clinical scales including the Beck Depression Inventory, the Hamilton Rating Scale for Depression, and the Major Depression Inventory.
Patients were categorized into two groups. One group received TMS alongside antidepressant treatment alone. The other group received TMS combined with antidepressants and antipsychotic augmentation.
The researchers also explored whether baseline resting motor threshold, a common physiological marker used in TMS dosing, correlated with treatment outcomes.
Using naturalistic clinical data allowed investigators to examine real-world treatment patterns rather than tightly controlled experimental conditions.
Early Differences But Similar Overall Outcomes
At the Augsburg site, researchers observed an interesting early pattern. Two weeks after treatment began, patients who were not receiving antipsychotic augmentation showed significantly greater improvement in depressive symptoms.
However, these differences did not persist over time. By the end of the TMS treatment course, symptom improvement between groups was no longer significantly different.
At the Regensburg site, investigators did not observe any consistent interaction between antipsychotic medication use and TMS response.
Across both datasets, the presence of antipsychotic medications did not appear to prevent patients from benefiting from TMS therapy.
Analyses of resting motor threshold also revealed no significant relationship with treatment outcomes, suggesting that baseline cortical excitability measures were not strongly predictive of clinical improvement in this dataset.
Why These Findings Matter For Real World TMS Practice
For clinicians delivering neuromodulation therapies, these results provide useful reassurance.
Patients receiving TMS frequently have complex medication regimens that include antipsychotic augmentation for treatment resistant depression. If these medications significantly interfered with stimulation based therapies, clinicians might need to adjust treatment protocols or medication plans.
Instead, the findings suggest that TMS with antipsychotic augmentation remains a viable treatment pathway.
The transient early difference observed at one site may reflect variations in patient populations, medication types, or other clinical variables rather than a consistent pharmacological interaction.
Importantly, the use of data from two independent clinics strengthens the ecological validity of the analysis.
Understanding The Neurobiological Interaction
Although antipsychotic medications affect dopamine and other neurotransmitter systems, their influence on cortical excitability is complex.
TMS works by inducing electrical currents in targeted cortical networks, which can influence synaptic plasticity and large scale brain connectivity.
Even if antipsychotic medications alter certain neurochemical pathways, the broader network level mechanisms of TMS may remain intact. This could explain why stimulation continues to produce clinical improvement in patients receiving these medications.
Further research using neurophysiological measures such as TMS EEG or functional imaging may help clarify how pharmacological and stimulation therapies interact.
Looking Ahead For Precision Neuromodulation
As interventional psychiatry continues to evolve, studies like this highlight the importance of understanding how different treatment modalities work together in real clinical settings.
Future investigations may examine whether specific antipsychotic medications interact differently with TMS protocols such as rTMS or iTBS. Researchers may also explore whether medication status influences optimal stimulation parameters.
For now, the available evidence suggests that TMS with antipsychotic augmentation remains a practical and effective option for many patients with treatment resistant depression.
Citations
Völkel A, Tritsch J, Poli M, et al. Antipsychotic co medication and treatment response to rTMS and iTBS in depression: Data from clinical records from two independent clinical sites. Journal of Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/41728831/
Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. The Lancet.
https://pubmed.ncbi.nlm.nih.gov/29726344/
Explore more at https://www.interventionalpsychiatry.org/